Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch
ALPHARETTA, Ga., July 8, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued a statement urging stockholders to follow the recommendation of Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, by voting AGAINST the election of Progenics directors Peter Crowley and Michael Kishbauch at the Company's upcoming Annual Meeting of Stockholders scheduled to be held on July 11, 2019 (the "Annual Meeting").
We have heard from numerous stockholders, who like Velan, are unhappy with the Progenics Board of Directors (the "Board"), particularly Peter Crowley and Michael Kishbauch, for overseeing years of stock underperformance, value-destructive behavior, unnecessary and persistent stockholder dilution, and entrenchment-minded tactics, all while collecting hefty paydays with minimal accountability.
The time to act is NOW. Velan has published a flyer for Progenics stockholders reminding them that time is short and stockholder action is necessary. Velan's flyer titled "ISS Agrees: Follow Velan's Lead and Vote AGAINST Crowley & Kishbauch" can be viewed by clicking the following link:
https://www.savepgnx.com/api/v1/files/e43dddf5-2478-47dc-3b02-08d6fbdf69f0
Stockholders have the opportunity to send a clear message to the Board that the troubling status quo is no longer tenable and that accountability in the boardroom is required. Each vote counts; Velan urges stockholders to vote TODAY.
FOLLOW ISS AND VOTE AGAINST MESSRS. CROWLEY AND KISHBAUCH TO ACHIEVE THE CHANGE DESPERATELY NEEDED AT PROGENICS.
Note: Permission to use quotations neither sought nor obtained. Emphasis added.
Investor contacts:
Deepak Sarpangal (415) 677-7050[email protected]www.savePGNX.com
Okapi Partners LLCPat McHugh / Jason Alexander+1 (888) 785-6673[email protected]
View original content:SOURCE Velan Capital, L.P.